X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will be used to fund company's Phase 3 clinical trial of VT-001 (atacicept), a fusion protein self-administered as a subcutaneous injection, in IgAN, regulatory submissions and, to the extent approved, preparation for commercial launch.
Lead Product(s): Atacicept
Therapeutic Area: Nephrology Product Name: VT-001
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $287.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 01, 2024
Details:
The net proceeds will be used to fund the development of the VT-001 (atacicept), which helps to produce autoantibodies contributing to certain autoimmune diseases including IgAN, also known as berger’s disease and lupus nephritis.
Lead Product(s): Atacicept
Therapeutic Area: Nephrology Product Name: VT-001
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $250.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 29, 2024
Details:
VT-001 (atacicept) is an investigational recombinant fusion protein that contains the soluble transmembrane activator and calcium-modulating cyclophilin ligand interactor receptor that binds to the cytokines B lymphocyte stimulator and a proliferation-inducing ligand.
Lead Product(s): Atacicept
Therapeutic Area: Nephrology Product Name: VT-001
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2023
Details:
The offering will be used to fund phase 3 trial of VT-001 (atacicept), a fusion protein that blocks both BLyS and a proliferation inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN.
Lead Product(s): Atacicept
Therapeutic Area: Nephrology Product Name: VT-001
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $115.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 06, 2023
Details:
The offering will be used to fund phase 3 trial of VT-001 (atacicept), a fusion protein that blocks both BLyS and a proliferation inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN.
Lead Product(s): Atacicept
Therapeutic Area: Nephrology Product Name: VT-001
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 01, 2023
Details:
TACI-IG (atacicept) is an investigational recombinant fusion protein that contains the soluble transmembrane activator and calcium-modulating cyclophilin ligand interactor receptor that binds to the cytokines B lymphocyte stimulator (BlyS) and a proliferation-inducing ligand.
Lead Product(s): Atacicept
Therapeutic Area: Nephrology Product Name: TACI-IG
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 30, 2023
Details:
TACI-IG (atacicept) is a recombinant fusion protein that contains the soluble transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI) receptor that binds to the cytokines B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL).
Lead Product(s): Atacicept
Therapeutic Area: Nephrology Product Name: TACI-IG
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 25, 2023
Details:
TACI-IG (Atacicept) is a recombinant fusion protein that contains the soluble TACI receptor that binds to the cytokines BLyS and APRIL, to reduce autoantibody production associated with IgA nephropathy (autoimmune disease).
Lead Product(s): Atacicept
Therapeutic Area: Nephrology Product Name: TACI-IG
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 03, 2023
Details:
Atacicept (TACI-IG), is the first therapeutic to show reduction in all of the three first hits of IgAN pathogenesis – serum galactose-deficient IgA1 (Gd-IgA1), anti-Gd-IgA1, and now immune complex levels.
Lead Product(s): Atacicept
Therapeutic Area: Nephrology Product Name: TACI-IG
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 05, 2022
Details:
TACI-IG (atacicept) is an investigational recombinant fusion protein that contains soluble transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI) receptor that binds to cytokines B lymphocyte stimulator (BlyS) and a proliferation-inducing ligand.
Lead Product(s): Atacicept
Therapeutic Area: Nephrology Product Name: TACI-IG
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 06, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
